Last reviewed · How we verify

Instituto Valenciano de Infertilidad, IVI VALENCIA — Portfolio Competitive Intelligence Brief

Instituto Valenciano de Infertilidad, IVI VALENCIA pipeline: 11 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 4 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
r-FSH plus HP-hMG r-FSH plus HP-hMG marketed Gonadotropin combination FSH receptor, LH receptor Reproductive Medicine / Fertility
COS with GnRH antagonists and HP-HMG COS with GnRH antagonists and HP-HMG marketed Gonadotropin protocol / Assisted reproductive technology regimen GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins) Reproductive Medicine / Infertility
COS with GnRH antagonists and rFSH COS with GnRH antagonists and rFSH marketed
Tryptorelin Tryptorelin marketed Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor Oncology
Cetrorelix and Leuprolide Cetrorelix and Leuprolide marketed GnRH antagonist and GnRH agonist combination GnRH receptor Reproductive Medicine / Fertility
Agonist GnRH; estradiol Valerate; progesterone Agonist GnRH; estradiol Valerate; progesterone marketed Hormone combination therapy; GnRH agonist with steroid hormones GnRH receptor; estrogen receptor; progesterone receptor Reproductive Medicine / Fertility
Antagonist GnRH Cetrotide Antagonist GnRH Cetrotide marketed GnRH antagonist GnRH receptor Reproductive Medicine / Fertility
Agonist GnRH Acetate Triptoreline Agonist GnRH Acetate Triptoreline marketed
r-FSH r-FSH marketed Gonadotropin FSH receptor (FSHR) Reproductive/Fertility
rFSH (Gonal®, rFSH (Gonal®, marketed Gonadotropin FSH receptor (FSHR) Reproductive Medicine / Infertility
Menopur®, Ferring Menopur®, Ferring marketed Gonadotropin FSH receptor (FSHR) and LH receptor (LHCGR) Reproductive Medicine / Fertility
Ganirelix (GnRH antagonist) Ganirelix (GnRH antagonist) phase 3 GnRH antagonist GnRH receptor Reproductive Medicine / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. El Shatby University Hospital for Obstetrics and Gynecology · 2 shared drug classes
  2. Merck KGaA, Darmstadt, Germany · 2 shared drug classes
  3. Ain Shams Maternity Hospital · 1 shared drug class
  4. Azienda USL Modena · 1 shared drug class
  5. Bezmialem Vakif University · 1 shared drug class
  6. Central Jutland Regional Hospital · 1 shared drug class
  7. D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 shared drug class
  8. Assaf-Harofeh Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto Valenciano de Infertilidad, IVI VALENCIA:

Cite this brief

Drug Landscape (2026). Instituto Valenciano de Infertilidad, IVI VALENCIA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-valenciano-de-infertilidad-ivi-valencia. Accessed 2026-05-17.

Related